2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0088
    Apocynin 498-02-2 99.94%
    Apocynin is a selective NADPH-oxidase inhibitor with an IC50 of 10 μM. Apocynin improves acute lung inflammation in Carrageenan (HY-125474)-induced pleurisy mice model. Apocynin can also be used for cancer research. Apocynin reverses the aging process in mesenchymal stem cells to promote osteogenesis and increases bone mass.
    Apocynin
  • HY-12940
    GLPG0974 1391076-61-1 98.12%
    GLPG0974 is a free fatty acid receptor-2 (FFA2/GPR43) antagonist with an IC50 of 9 nM.
    GLPG0974
  • HY-15253
    Tiplaxtinin 393105-53-8 99.03%
    Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 μM.
    Tiplaxtinin
  • HY-15858
    AP-III-a4 1177827-73-4 ≥98.0%
    AP-III-a4 (ENOblock) is a nonsubstrate analogue enolase inhibitor with an IC50 of 0.576 uM. AP-III-a4 can be used for the research of cancer and diabetic.
    AP-III-a4
  • HY-14268
    Febuxostat 144060-53-7 99.94%
    Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout.
    Febuxostat
  • HY-P9930
    Evolocumab 1256937-27-5
    Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation.
    Evolocumab
  • HY-B0456
    Riboflavin 83-88-5 ≥98.0%
    Riboflavin, an orally active and easily absorbed micronutrient, is a precursor of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), which serve as coenzymes for numerous enzymatic reactions and perform key metabolic functions by mediating the transfer of electrons in biological oxidation-reduction reaction.
    Riboflavin
  • HY-N0469
    L-Lysine 56-87-1 ≥98.0%
    L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation.
    L-Lysine
  • HY-103701
    L-Ascorbic acid 2-phosphate 23313-12-4
    L-ascorbic acid 2-phosphate (2-Phospho-L-ascorbic acid) is a long-acting vitamin C derivative that can stimulate collagen formation and expression. L-ascorbic acid 2-phosphate (2-Phospho-L-ascorbic acid) can be used as a culture medium supplement for the osteogenic differentiation of human adipose stem cells (hASCs). L-ascorbic acid 2-phosphate increases alkaline phosphatase (ALP) activity and expression of runx2A in hASCs during the osteogenic differentiation.
    L-Ascorbic acid 2-phosphate
  • HY-13524
    AG-1478 153436-53-4 99.57%
    AG-1478 (Tyrphostin AG-1478) is a selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM. AG-1478 has antiviral effects against HCV and encephalomyocarditis virus (EMCV).
    AG-1478
  • HY-10838
    GW 501516 317318-70-0 99.27%
    GW 501516 (GW 1516) is a PPARδ agonist with an EC50 of 1.1 nM.
    GW 501516
  • HY-135425
    10,12-Tricosadiynoic acid 66990-30-5 99.05%
    10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism. 10,12-Tricosadiynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    10,12-Tricosadiynoic acid
  • HY-N0830S6
    Palmitic acid-13C16 56599-85-0 ≥99.0%
    Palmitic acid-13C16 is the 13C-labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. PA can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-13C16
  • HY-B1352
    L-Ornithine 70-26-8 ≥98.0%
    L-Ornithine ((S)-2,5-Diaminopentanoic acid) is a non-proteinogenic amino acid, is mainly used in urea cycle removing excess nitrogen in vivo. L-Ornithine shows nephroprotective.
    L-Ornithine
  • HY-125824
    Danuglipron 2230198-02-2 99.85%
    Danuglipron (PF-06882961) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist. Danuglipron has the potential for type 2 diabetes research.
    Danuglipron
  • HY-P1944A
    Apelin-13 TFA 99.53%
    Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome.
    Apelin-13 TFA
  • HY-107454
    OSS_128167 887686-02-4 98.63%
    OSS_128167 is a potent selective sirtuin 6 (SIRT6) inhibitor with IC50s of 89 μM, 1578 μM and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects.
    OSS_128167
  • HY-P99930
    Efruxifermin 2375240-92-7 98.32%
    Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis.
    Efruxifermin
  • HY-P3462
    Cagrilintide 1415456-99-3 99.17%
    Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity.
    Cagrilintide
  • HY-N0832
    L-Histidine 71-00-1
    L-Histidine is an essential amino acid for infants. L-Histidine is an inhibitor of mitochondrial glutamine transport.
    L-Histidine
Cat. No. Product Name / Synonyms Application Reactivity